GZD-552 |
Catalog No.GC81328
One-Click Copy Product Info
|
GZD-552 is a potent orally active FAK inhibitor with a human FAK IC50 of 5.8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, GZD-552 (compound 16c) (10 and 20 mg/kg/day; i.g.; daily; 18 days) inhibits tumor growth in mouse U87-MG xenograft model without detectable systemic toxicity[1].
In Vitro, GZD-552 (compound 16c) potently and selectively inhibits the proliferation of U87-MG and U118-MG glioblastoma cells with IC50 values of 6.6 nM and 4.3 nM, respectively, and shows limited activity against NCI-H1975 (IC50 = 0.16 μM), MDA-MB-231 (IC50 = 0.28 μM), and LO2 cells (IC50 = 0.74 μM)[1]. GZD-552 strongly and stably binds to FAK protein in U87-MG cells[1]. GZD-552 (0.002-0.08 μM) suppresses FAK protein expression and activation, and downregulates downstream ERK phosphorylation in U87-MG cells in a concentration-dependent manner[1]. GZD-552 (0.004-0.12 μM; 24 h) induces dose-dependent apoptosis and G2/M cell cycle arrest in U87-MG cells[1].
References:
[1]. Xu Y, et al. Design, synthesis, and anti-glioblastoma multiforme evaluation of novel multikinase inhibitors via a cyclization strategy with potent FAK inhibition. Eur J Med Chem. 2026;312:118877.
| Cas No. | SDF | ||
| Formula | C27H30F3N5O6 | M.Wt | 577.55 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7315 mL | 8.6573 mL | 17.3145 mL |
| 5 mM | 346.3 μL | 1.7315 mL | 3.4629 mL |
| 10 mM | 173.1 μL | 865.7 μL | 1.7315 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)